HCL group founder Shiv Nadar has gifted 47 per cent of his stake in HCL Corp and Vama Delhi, the promoter entities of the group, to his daughter Roshni Nadar Malhotra, in a strategic transfer as part ...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc ... receptor and µ-opioid peptide (MOP) receptor (dual-NMR) agonism. This dual-NMR agonist has the potential to deliver significant ...

Privately-held US drugmaker Tris Pharma today announced positive top-line results from its ALLEVIATE-2 Phase ... receptor and µ-opioid peptide (MOP) receptor (dual-NMR) agonism. This dual-NMR agonist ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to ...

The reaction conditions were as follows: 100 μl lysis enzyme (approximately 1 μM aMOx), 5 mM substrate, 10 mM NADPH, and 25 mM Tris-HCl at pH 8.0 to make up the reaction volume of ... and ...

Recombinant Zn 7 GIF/MT-3 was incubated with 0.1 N HCl for 30 min and then replaced with 20 mM Tris-HCl (pH 7.5) buffer for 36 h at 37°C (apo-GIF/MT-3 ... NP_005945.1), the crystal structure of rat MT ...

After overnight dehumidification under room temperature, the slides were washed with MilliQ water and subsequently blocked with 50 mM ethanolamine in 100 mM Tris-HCl (pH 9.0) for 2 h. The blocked ...

After 4 days of incubation, cell media were centrifuged for 3 min at 300 × g and 4.500 × g, filtered through 0.2 µm cellulose acetate membrane (Waters) and dialyzed against 500 ml 20 mM Tris-HCl pH 8, ...